Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 23, 2007

Novartis Licenses MedImmune’s Reverse Genetics Technology for Flu Vaccines

  • MedImmune licensed its reverse genetics intellectual property to Novartis. The transaction will support the development and construction of new vaccine strains to produce inactivated human seasonal, prepandemic, and pandemic influenza vaccines.

    MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products.

    Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For prospective pandemic influenza vaccines, it can be a useful technology because the process does not require manufacturers to work directly with potentially infectious pandemic strains such as H5N1 rather only segments of the virus’ genome, according to MedImmune.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »